Arcutis Biotherapeutics, Inc.
Symbol: ARQT
NASDAQ
7.99
USDMarknadspris idag
-2.8257
P/E-tal
0.0000
PEG-kvot
923.04M
MRK Aktiekapital
- 0.00%
DIV Avkastning
{{företagets_namn}} (ARQT) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1100.97 | 272.8 | 409.6 | 387.1 | |||||||
balance-sheet.row.short-term-investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.net-receivables | 75.2 | 25.8 | 8.5 | 0.4 | |||||||
balance-sheet.row.inventory | 46.07 | 13.1 | 7.5 | 1.2 | |||||||
balance-sheet.row.other-current-assets | 63.5 | 18.7 | 10.6 | 14.2 | |||||||
balance-sheet.row.total-current-assets | 1288.52 | 330.4 | 437.4 | 402.8 | |||||||
balance-sheet.row.property-plant-equipment-net | 17.21 | 3.9 | 4.6 | 5.3 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 1.87 | 0.6 | 0.1 | 0.1 | |||||||
balance-sheet.row.total-non-current-assets | 45.95 | 10.9 | 11.9 | 5.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.account-payables | 54.81 | 12 | 8.8 | 7.4 | |||||||
balance-sheet.row.short-term-debt | 2.82 | 0.7 | 0.7 | 0.4 | |||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.long-term-debt-total | 812.38 | 201.8 | 201.9 | 77.1 | |||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 104.61 | 33.9 | 28.3 | 25.5 | |||||||
balance-sheet.row.total-non-current-liabilities | 816.61 | 206 | 201.9 | 77.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 16.73 | 3.4 | 4.8 | 5.2 | |||||||
balance-sheet.row.total-liab | 978.85 | 252.7 | 239.7 | 110.5 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||
balance-sheet.row.retained-earnings | -3568.24 | -981.9 | -719.8 | -408.3 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.89 | 0 | -1.1 | -0.3 | |||||||
balance-sheet.row.other-total-stockholders-equity | 3924.73 | 1070.6 | 930.4 | 706.2 | |||||||
balance-sheet.row.total-stockholders-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 1334.47 | - | - | - | |||||||
Total Investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.total-debt | 818.58 | 205.9 | 202.5 | 77.6 | |||||||
balance-sheet.row.net-debt | 435.26 | 116.6 | 148.9 | -18.9 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -262.14 | -262.1 | -311.5 | -206.4 | |||||||
cash-flows.row.depreciation-and-amortization | 1.52 | 1.9 | 0.9 | 0.5 | |||||||
cash-flows.row.deferred-income-tax | -19.69 | 19.8 | 0 | 3.5 | |||||||
cash-flows.row.stock-based-compensation | 38.81 | 38.8 | 32.7 | 23.9 | |||||||
cash-flows.row.change-in-working-capital | -23.5 | -23.5 | -10.2 | 3.6 | |||||||
cash-flows.row.account-receivables | -17.35 | -17.3 | -8.5 | 0 | |||||||
cash-flows.row.inventory | -5.62 | -5.6 | -7.5 | 0 | |||||||
cash-flows.row.account-payables | 3.15 | 3.2 | 1.6 | 0.2 | |||||||
cash-flows.row.other-working-capital | -3.68 | -3.7 | 4.2 | 3.4 | |||||||
cash-flows.row.other-non-cash-items | 17.94 | -21.9 | 30.3 | 0.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | -247.06 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.acquisitions-net | -180.66 | 0 | 22.9 | 75 | |||||||
cash-flows.row.purchases-of-investments | -225.84 | -225.8 | -415.4 | -292.5 | |||||||
cash-flows.row.sales-maturities-of-investments | 406.5 | 406.5 | 351.5 | 217.6 | |||||||
cash-flows.row.other-investing-activites | 180.66 | 0 | -22.9 | -75 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 180.23 | 180.2 | -87.2 | -76 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.common-stock-issued | 100.26 | 101.3 | 176 | 207.5 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 12.5 | 0.8 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.other-financing-activites | 101.32 | 5.6 | 358.9 | 218.3 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 101.32 | 101.3 | 301.8 | 281.9 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.05 | -0.1 | 0 | 0 | |||||||
cash-flows.row.net-change-in-cash | 34.45 | 34.4 | -43.1 | 31.4 | |||||||
cash-flows.row.cash-at-end-of-period | 386.09 | 89.3 | 54.9 | 98 | |||||||
cash-flows.row.cash-at-beginning-of-period | 351.64 | 54.9 | 98 | 66.6 | |||||||
cash-flows.row.operating-cash-flow | -247.06 | -247.1 | -257.7 | -174.6 | |||||||
cash-flows.row.capital-expenditure | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.free-cash-flow | -247.49 | -247.5 | -281 | -175.6 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 59.61 | 59.6 | 3.7 | 0 | |||||||
income-statement-row.row.cost-of-revenue | 5.18 | 6.1 | 0.8 | 0.8 | |||||||
income-statement-row.row.gross-profit | 54.42 | 53.5 | 2.9 | -0.8 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 110.58 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 235.81 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.other-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.operating-expenses | 295.52 | 294.6 | 304.6 | 206.5 | |||||||
income-statement-row.row.cost-and-expenses | 300.71 | 300.7 | 305.3 | 206.5 | |||||||
income-statement-row.row.interest-income | 12.9 | 0 | 9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.total-operating-expenses | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 6.7 | 1.9 | 5.8 | 0.5 | |||||||
income-statement-row.row.ebitda-caps | -231.67 | - | - | - | |||||||
income-statement-row.row.operating-income | -241.1 | -241.1 | -301.6 | -206.5 | |||||||
income-statement-row.row.income-before-tax | -259.09 | -259 | -311.5 | -206.4 | |||||||
income-statement-row.row.income-tax-expense | 12.77 | 3.1 | 9.8 | -0.5 | |||||||
income-statement-row.row.net-income | -261.78 | -262.1 | -321.3 | -205.9 |
Ofta ställda frågor
Vad är Arcutis Biotherapeutics, Inc. (ARQT) totala tillgångar?
Arcutis Biotherapeutics, Inc. (ARQT) totala tillgångar är 341365000.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 51635000.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.913.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -2.673.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är -4.392.
Vad är företagets totala intäkter?
Totala intäkter är -4.045.
Vad är Arcutis Biotherapeutics, Inc. (ARQT) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är -262140000.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 205916000.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 294589000.000.
Vad är företagets kassaflöde?
Företagets kassa är 89323000.000.